NCT02130557 2021-05-18A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous LeukemiaPfizerPhase 3 Completed536 enrolled 24 charts 1 FDA
NCT01650805 2014-11-17Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)Ariad PharmaceuticalsPhase 3 Terminated307 enrolled 11 charts